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ABSTRACT. Objective. To prospectively evaluate the disease course and the performance of clinical,
patient-reported outcome (PRO) and musculoskeletal ultrasound measures in patients with
polymyalgia rheumatica (PMR).
Methods. The study population included 85 patients with new-onset PMR who were initially treat-
ed with prednisone equivalent dose of 15 mg daily tapered gradually, and followed for 26 weeks.
Data collection included physical examination findings, laboratory measures of acute-phase reac-
tants, and PRO measures. Ultrasound evaluation was performed at baseline and Week 26 to assess
for features previously reported to be associated with PMR. Response to corticosteroid treatment
was defined as 70% improvement in PMR on visual analog scale (VAS).
Results. At baseline, 77% had hip pain in addition to shoulder pain and 100% had abnormal C-reac-
tive protein or erythrocyte sedimentation rate. On ultrasound, 84% had shoulder findings and 32%
had both shoulder and hip findings. Response to corticosteroid treatment occurred in 73% of patients
by Week 4 and was highly correlated with percentage improvement in other VAS measures. Presence
of ultrasound findings at baseline predicted response to corticosteroids at 4 weeks. Factor analysis
revealed 6 domains that sufficiently represented all the outcome measures: PMR-related pain and
physical function, an elevated inflammatory marker, hip pain, global pain, mental function, and
morning stiffness.
Conclusion. PRO measures and inflammatory markers performed well in assessing disease activity
in patients with PMR. A minimum set of outcome measures consisting of PRO measures of pain and
function and an inflammatory marker should be used in practice and in clinical trials in PMR. 
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Polymyalgia rheumatica (PMR) is the most common
inflammatory rheumatic disease of the elderly and repre-
sents the most common indication for longterm cortico -
steroid therapy in the community1,2,3. There is wide varia-
tion in management of PMR in the clinical setting, in part
due to the uncertainties related to diagnosis and the hetero-
geneous and unpredictable disease course. Corticosteroid
(CS) treatment lasts for several years and can result in seri-
ous adverse effects, of which osteoporosis, fractures, dia-
betes, and infections are among the worst4. As a result, treat-
ment of PMR remains largely empiric5,6.
Uniform responsiveness to low doses of CS has been
assumed to be a cardinal feature of PMR. It is included in
several popular diagnostic criteria and is commonly used by
clinicians in both primary and secondary care to make a
diagnosis of PMR. However, there is little hard evidence to
substantiate this, and a previous prospective inception
cohort study of PMR showed that, 3 weeks after starting
prednisolone 15 mg daily, more than 55% of patients failed
a complete response to therapy as defined by greater than
70% improvement in pain, morning stiffness less than
half-hour, and normal inflammatory markers7. This empha-
sizes the need for clinical trials of disease-modifying
antirheu matic drugs and novel agents in order to improve
treatment efficacy in PMR.
The 2 foremost factors that have hampered development
of new therapeutic approaches to management of PMR are,
first, lack of standardized classification criteria for inclusion
of subjects with PMR in clinical trials, and second, lack of
reliable, valid, and sensitive outcome measures. These defi-
ciencies have led to an inability to accurately distinguish
this clinical disease entity from other conditions presenting
with the polymyalgic syndrome, and difficulty with evalua-
tion and comparison of the efficacy of different therapeutic
approaches, including novel drug therapies. Better and vali-
dated measures to evaluate disease activity and outcomes
may also help to reduce the CS treatment burden in the daily
practice of PMR management.
In order to tackle these challenges, an international PMR
Classification Criteria Work Group initiated a multinational
effort in 2005 and recently proposed new classification cri-
teria for PMR8. Candidate classification criteria were devel-
oped through consensus meetings and a wider survey. The
performance characteristics of the candidate criteria items
were then analyzed in a 6-month prospective study of
patients presenting with new-onset bilateral shoulder pain.
PMR cases were recruited prior to steroid therapy and treat-
ed with standardized doses of CS. As part of the same effort,
the work group collected prospective data on various out-
come measures in patients with PMR. The initial face and
content validity of our proposed set of outcome measures
were evaluated through the previous consensus meetings
and Delphi surveys8,9. 
We report on the disease course of patients with PMR
over a 6-month period following disease onset. The goal of
our study was to prospectively evaluate the performance of
various clinical, laboratory, and patient-reported outcome
(PRO) measures and musculoskeletal ultrasound findings in
patients with PMR, and to identify a minimum set of out-
come measures that can be used in practice and in future
clinical trials.
MATERIALS AND METHODS
Study population. Our study was conducted as part of a prospective cohort
study aimed at developing classification criteria for PMR8. Assessment of
outcome measures was planned as part of the original study. Briefly, the
study population included a cohort of patients with new-onset PMR recruit-
ed at 21 community-based and academic rheumatology clinics in 10
European countries and the United States. Inclusion criteria for patients
with PMR were age ≥ 50 years, new-onset bilateral shoulder pain, and no
corticosteroid treatment (for any condition) within the 12 weeks prior to
study entry, who fulfilled all the inclusion criteria [i.e., morning stiffness >
45 min, raised markers of C-reactive protein (CRP) and/or erythrocyte sed-
imentation rate (ESR)] and exclusion criteria at presentation [i.e., no infec-
tion, active cancer, giant cell arteritis (GCA), or clinical features of the
common PMR mimics] as defined by our previous report and in accord
with expert clinician judgment of the participating investigator that the
patient had PMR10. The clinical disease manifestations represented the
clinical spectrum of PMR disease from mild to severe, but excluding
patients with GCA. The “gold standard” for the presteroid diagnosis of
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PMR was established as above at presentation and where the diagnosis was
maintained without an alternative diagnosis at Week 26 of followup.
Analyses of outcome measures included only the subset of patients who
met the proposed classification criteria for PMR, i.e., a score ≥ 4 based on
morning stiffness > 45 min (2 points), hip pain/limited range of motion (1
point), normal rheumatoid factor and/or anticitrullinated protein antibodies
(2 points), and absence of peripheral joint pain (1 point)8. Adding 1 point
for typical ultrasound findings increased sensitivity and specificity of the
criteria8. To establish evaluation measures for ultrasonographic findings,
we conducted ultrasonography of the target joint structures in 21 compara-
tor subjects who had no history of musculoskeletal diseases.
During the 6-month duration of the study, CS treatment for the majori-
ty of the patients with PMR was maintained according to a predefined treat-
ment protocol starting with 15 mg daily oral prednisone equivalent (pred-
nisone or prednisolone) for Weeks 1 and 2, 12.5 mg daily for Weeks 3 to 5,
10 mg daily for Weeks 6 to 11, 10 mg/7.5 mg every other day for Weeks 12
to 15, 7.5 mg daily for Weeks 16 to 25, and tapering according to treatment
response from Week 26 onward.
Followup and data collection. All patients with PMR were evaluated at
baseline, 1 week, 4 weeks, 12 weeks, and at 26 weeks according to a stan-
dardized protocol. At each followup visit, clinical evaluation included opin-
ion of the treating physicians on emergence of alternative diagnoses.
Patients not considered as having PMR at any time during followup were
excluded from the analysis. Data were collected using standardized data
collection forms and patient questionnaires translated into national
 languages.
Standardized data collection forms included various inclusion/exclu-
sion criteria items for classification of PMR (summarized previously8),
signs and symptoms, physical examination findings, laboratory measures
of acute-phase reactants (ESR, CRP), and PRO measures corresponding to
various important domains in PMR. Physical examination included pres-
ence or absence of tenderness and pain on movement and limitation of the
shoulders and hips. Aspects of CS therapy including change in dose and
discontinuation of therapy were documented. Data regarding laboratory
measures (ESR, CRP) were obtained from clinically ordered tests per-
formed at each study center. Since values from laboratory assays used at
each center varied, test results were classified as normal/abnormal using the
reference ranges from each center (Table 1). A 100-mm visual analog scale
(VAS) was used for recording global pain measures (shoulder pain, hip
pain, global pain, and PMR) and fatigue, with 0 indicating no pain or
fatigue and 100 indicating worst pain or fatigue. Data on PMR VAS scale
were derived based on patients’ responses to the following question, “On a
scale from no effect to maximum effect, how would you rate how your
PMR affects you today?”. Morning stiffness was assessed by directly ques-
tioning the patient on duration of morning stiffness in minutes in the last 24
h. Functional status and quality of life were assessed using the modified
Health Assessment Questionnaire (MHAQ) and Medical Outcomes Study
Short Form-36 (SF-36)11,12. The SF-36 yields physical component summa-
ry (PCS) and mental component summary (MCS) scores that range from 0
to 100, 0 indicating the least favorable and 100 the most favorable score.
Patients who were seen at clinics with musculoskeletal ultrasound
availability and expertise underwent ultrasound evaluation of the shoulders
and hips at baseline visit and at Week 26 of followup. Ultrasound evalua-
tion was performed according to European League Against Rheumatism
guidelines to assess for features previously reported to be associated with
PMR, including bicipital tenosynovitis, subacromial and subdeltoid bursi-
tis, trochanteric bursitis, and glenohumeral and hip effusion13. A rheuma-
tologist or radiologist experienced in musculoskeletal ultrasound of shoul-
ders and hips performed the ultrasound examinations at each participating
institution. For the shoulders, linear probes providing frequency range 6–10
MHZ and for the hips linear or curved array probes with frequency range
5–8 MHZ were used. Ultrasound measures were also obtained at 1 institu-
tion for a group of 21 subjects with normal health for comparison to
patients with PMR.
Statistical analysis. Descriptive statistics (percentages, medians, interquar-
tile ranges, etc.) were used to summarize the data. Comparisons between
patients at different timepoints were performed using paired t tests for con-
tinuous measures and McNemar’s test of agreement for dichotomous
 measures.
Logistic regression models were used to examine potential predictors of
response to CS treatment at Weeks 1, 4, and 26. Potential predictors includ-
ed age, sex, and baseline disease characteristics including PRO and ultra-
sound measures.
Test-retest reliability of continuous measures was assessed in a subset
of patients who reported little change (± 10 mm) on PMR VAS between
baseline and Week 1 visits using intraclass correlation coefficient (2,1)14.
The smallest detectable difference (SDD), a measure of reliability or preci-
sion, was also estimated15. SDD is a measure of the smallest difference for
which anything smaller cannot be distinguished from random measurement
error. The percentage minimal detectable change (%MDC) expressed the
SDD as a percentage of the maximum possible score, which allows com-
parison of reliability across outcome measures.
Exploratory factor analysis was used to examine the interdependencies
between outcome measures16. Maximum likelihood factor analysis with
varimax rotation was used. Maximum likelihood tests were used to exam-
ine goodness-of-fit (e.g., to determine the number of factors). This method
is thought to be superior to the eigen value > 1 or Cattell’s scree plot
method for selecting the number of factors16. This technique identified
potential domains to help group the outcome measures. For each factor,
variables with factor loadings > 0.5 were considered to measure similar
constructs. Internal consistency (i.e., the degree to which outcome meas-
797Matteson, et al: Patient-reported outcomes in PMR
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Table 1. Test results were classified as normal/abnormal using the refer-
ence ranges from each center.
Center ESR, CRP, RF, ACPA,
mm/h mg/l IU/ml U/ml
1 < 25 < 5 < 40 < 20
2 2–37 in 1st hour < 5 < 30 0–10
4 < 10 < 5 < 40 < 20
6 < 8 in 1st hour, < 5 < 14 < 10
< 18 in 2nd hour
8 (2 sites) 0–9 < 5 0–13 0–6
< 8 0–14 0–10
13 Female 2–20 < 10 < 16 < 7
Male 2–15
14 Male: yrs divided by 2 < 5 1–20 < 25
Female: yrs + 10 divided by 2
18 1–20 < 10 < 25 < 25
20 < 15 < 5 < 50 < 50
21 < 28 < 5 < 20 < 26
22 < 30 < 5 < 20 < 10
23 < 37 < 10 16 < 8
24 < 37 < 10 16 < 8
25 1–15 < 10 < 40 < 7
30 < 37 < 10 16 < 8
31 0–29 < 8 < 10 < 15.6
32 Male 0–22 ≤ 8 < 10 < 15.6
Female 0–29
33 0–29 < 8 < 14 < 20
34 < 20 < 8 < 14 < 16
40 < 20 women < 5 1–20 < 251
< 14 men
41 Women: (age + 10)/2 ≤ 8 ≤ 35 < 7, negative;
Men: age/2 > 10 positive
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF:
rheumatoid factor; ACPA: anticitrullinated protein antibodies.
 Journal of Rheumatology
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ures in the same domain hold together, or the degree to which they meas-
ure the same underlying construct) was determined by Cronbach’s alpha,
with cutoff values > 0.9 as indication of perfect consistency (or redundan-
cy) and < 0.6 as poor consistency17. 
RESULTS
The study population included 85 patients with new-onset
PMR who were initially treated with prednisolone/pred-
nisone 15 mg daily tapered gradually, and assessed at base-
line and Weeks 1, 4, 12, and 26 following start of CS thera-
py. Their mean age was 72.6 years (minimum 52, maximum
95) and 60% were women.
At initial presentation, all patients had shoulder pain and
abnormal CRP and/or ESR, and 77% had hip pain (Table 2).
Median duration of morning stiffness was 120 minutes with
median PMR VAS 66, global pain VAS 59, fatigue VAS 58,
and median MHAQ score 1.1. With the exception of the
MCS, significant improvements between baseline and Week
1 were noted in all outcome measures (p < 0.001 for all;
Table 2 and Figure 1). Between Weeks 1 and 4, improve-
ments were noted in all outcome measures, but the improve-
ment in fatigue VAS (median 20 at Week 1 vs median 11 at
Week 4) did not achieve statistical significance (p = 0.10).
Similarly, the improvement in the percentage of patients
with hip pain (31% at Week 1 vs 23% at Week 4) did not
reach statistical significance (p = 0.09). Of note, a signifi-
cant improvement in MCS was noted between Weeks 1 and
4 (p = 0.004). The majority of outcome measures did not
improve significantly between Weeks 4 and 26. However,
the MHAQ continued to improve between Weeks 4 (median
0.1) and 26 (median 0; p = 0.03). As expected by the plan
for tapering the CS treatment, the median prednisone dose
decreased from 15 mg at baseline to 5 mg at 26 weeks.
Steroid doses above the level specified in the protocol were
required for 15% of patients at Week 4 and for 15% of
patients at Week 26.
Ultrasound findings. Ultrasound data were available for 82
patients (Table 3). On ultrasound examination at baseline,
84% had at least 1 shoulder with findings of subdeltoid bur-
sitis, biceps tenosynovitis or glenohumeral synovitis, 57%
had both shoulders with subdeltoid bursitis, biceps tenosyn-
ovitis or glenohumeral synovitis, and 32% had at least 1 of
these ultrasound findings in at least 1 shoulder and 1 hip. All
ultrasound measures improved significantly between base-
line and Week 26 (p < 0.001 for all). We also compared
these ultrasound findings with a group of 21 normal subjects
(mean age 67 yrs, minimum 62, maximum 71; 76%
women). Significant differences between patients with PMR
and normal subjects were noted for all ultrasound measures
at baseline except the percentage of patients with ultrasound
findings in both shoulders and both hips (16% in PMR vs
0% in normal subjects; p = 0.05). At Week 26, ultrasound
findings involving the shoulders remained significantly
higher among patients with PMR than among normal sub-
jects, but the percentage with ultrasound findings of the hips
or the hips and shoulders combined were not significantly
elevated in patients with PMR compared to normal subjects.
798 The Journal of Rheumatology 2012; 39:4; doi:10.3899/jrheum.110977
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Table 2. Clinical and patient-reported outcomes in patients with polymyalgia rheumatica (PMR). Percentages are calculated using available (nonmissing)
data. The proportion of patients without C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) measurements was similar for all visits.
Feature Baseline Week 1 Week 4 Week 12 Week 26 p, Baseline p, Week 1 p, Week 4
n = 85 n = 77 n = 79 n = 77 n = 81 vs Week 1 vs Week 4 vs Week 26
Shoulder pain, n (%) 85 (100) 52 (68) 33 (42) 25 (32) 24 (30) < 0.001 < 0.001 0.51
Hip pain, n (%) 65 (77) 24 (31) 18 (23) 6 (8) 13 (16) < 0.001 0.09 0.32
Morning stiffness duration, 120 (80, 240) 15 (0, 30) 0 (0, 10) 0 (0, 0) 0 (0, 2.5) < 0.001 0.001 0.18
min, median (IQR)
PMR VAS, median (IQR) 66 (46, 84) 20 (8, 44) 6 (2, 26) 4 (0, 11) 4 (1, 14) < 0.001 < 0.001 0.79
Global pain VAS, median (IQR) 59 (47, 83) 20 (7, 43) 7 (2, 18) 4 (0, 13) 6 (2, 20) < 0.001 < 0.001 0.70
Shoulder pain VAS, median (IQR) 60 (42, 82) 22 (5, 47) 6 (2, 22) 3 (0, 10) 4 (1, 13) < 0.001 < 0.001 0.30
Hip pain VAS, median (IQR) 47 (17, 71) 8 (1, 28) 3 (0, 13) 2 (0, 8) 3 (0, 9) < 0.001 0.004 0.63
Fatigue VAS, median (IQR) 58 (35, 78) 20 (9, 41) 11 (2, 34) 8 (0, 30) 8 (1, 27) < 0.001 0.10 0.15
MHAQ, median (IQR) 1.1 (0.8, 1.7) 0.3 (0.1, 0.8) 0.1 (0, 0.4) 0 (0, 0.1) 0 (0, 0.1) < 0.001 < 0.001 0.031
SF-36 PCS, median (IQR) 35 (31, 40) 42 (35, 46) 46 (41, 50) 49 (43, 51) 48 (39, 51) < 0.001 < 0.001 0.50
SF-36 MCS, median (IQR) 46 (41, 52) 45 (40, 51) 49 (43, 52) 49 (45, 52) 50 (46, 53) 0.46 0.004 0.43
Abnormal ESR, n (%) 74 (90) 30 (60) 19 (30) 24 (35) 19 (31) < 0.001 < 0.001 0.25
Abnormal CRP, n (%) 77 (95) 18 (38) 12 (23) 12 (20) 10 (18) < 0.001 0.035 0.53
Abnormal CRP or ESR, n (%) 85 (100) 40 (73) 23 (35) 26 (38) 23 (35) — < 0.001 0.32
Prednisone dosage, median (IQR), mg 15 (15, 15) 15 (13.8, 15) 12.5 (12.5, 12.5) 8.8 (7.5, 10) 5.1 (5, 7.5) 0.13 < 0.001 < 0.001
Prednisone dosage, n (%) — — —
Below protocol 13 (15) 17 (22) 17 (22) 8 (10) 0 (0)
On protocol 66 (78) 48 (62) 50 (63) 57 (74) 69 (85)
Above protocol 6 (7) 12 (16) 12 (15) 12 (16) 12 (15)
IQR: interquartile range (25th percentile, 75th percentile); MHAQ: modified Health Assessment Questionnaire; VAS: visual analog scale; PCS: physical com-
ponent score of the Short-Form 36 (SF-36); MCS: mental component score of the Short-Form 36.
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Figure 1. Change from visit to visit in patient-reported outcomes, erythrocyte sedimentation rate (ESR), and C-reactive
protein (CRP) in patients with polymyalgia rheumatica (PMR). VAS: visual analog scale; MHAQ: modified Health
Assessment Questionnaire; SF-36: Medical Outcomes Study Short Form-36; PCS: physical component summary; MCS:
mental component summary.
 Journal of Rheumatology
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Response to corticosteroids. Response to CS treatment
(defined as 70% improvement in PMR VAS) occurred in a
majority (73%) of the patients by Week 4 and in 80% of
patients by Week 12 (Table 4). Improvement of 70% by
Week 4 was also noted in 70% of patients for global pain
VAS and in 52% of patients for fatigue VAS. Response to
treatment (percentage improvement in PMR VAS at Weeks
4 and 26) was highly correlated with percentage improve-
ment in other VAS measures (correlation > 0.5 and p < 0.001
at Weeks 4 and 26), but was not correlated with change in
CS dose (p = 0.24 at Week 4; p = 0.41 at Week 26). There
was no association between severity of PMR at baseline (as
measured by VAS, abnormal CRP and/or ESR, MHAQ,
SF-36 PCS, SF-36 MCS, or ultrasound) and response to CS
treatment at Week 1 or Week 26. The presence of ultrasound
findings of at least 1 hip with synovitis and/or trochanteric
bursitis at baseline was associated with response to CS at
Week 4 (OR 3.6, 95% CI 0.9, 14.4; p = 0.06). Similarly, the
presence of ultrasound findings of at least 1 shoulder with
subdeltoid bursitis and/or biceps tenosynovitis and/or gleno-
humeral synovitis AND at least 1 hip with synovitis and/or
trochanteric bursitis was significantly associated with
response to CS at Week 4 (OR 3.1, 95% CI 0.8, 12.1; p =
0.10). Patients with lower baseline SF-36 MCS were also
more likely to respond to CS treatment at Week 4 (OR 0.88,
95% CI 0.81, 0.97; p = 0.006).
Complete response was defined as all 3 of the following:
(1) ≥ 70% improvement in PMR VAS; (2) ≥ 70% reduction
in duration of morning stiffness; and (3) normal CRP and/or
ESR. Partial response was defined as 2 of the 3, and non -
response was none or 1 of the 3. At Week 4, complete
response was achieved by 53% of patients and partial
response occurred in 32% of patients. At Week 26, complete
response was reported in 56% of patients and partial
response was reported in 33% of patients.
The test-retest reliability of patient self-reported meas-
ures was evaluated in 14 patients with PMR who had mini-
mal change in PMR VAS (± 10 mm) between baseline and
Week 1 (Table 5). Intraclass correlation coefficients (ICC)
revealed poor reliability (defined as ICC < 0.6) for fatigue
VAS, morning stiffness, and SF-36 MCS. The SDD was also
large (> 50) for fatigue VAS.
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Table 3. Ultrasound findings in patients with polymyalgia rheumatica and normal subjects. Data are no. (%).
Feature Week 0, Week 26, Healthy Subjects, p, Week 0 p, Week 26
n = 82 n = 74* n = 21 vs Healthy vs Healthy
At least ONE shoulder with subdeltoid bursitis, biceps tenosynovitis, 69 (84) 36 (49) 4 (19) < 0.001 0.015
or glenohumeral synovitis
BOTH shoulders with subdeltoid bursitis, biceps tenosynovitis, 47 (57) 18 (24) 0 (0) < 0.001 0.012
or glenohumeral synovitis
At least ONE shoulder with subdeltoid bursitis or biceps tenosynovitis 68 (84) 33 (45) 4 (19) < 0.001 0.034
BOTH shoulders with subdeltoid bursitis or biceps tenosynovitis 46 (56) 15 (20) 0 (0) < 0.001 0.025
At least ONE hip with synovitis or trochanteric bursitis 27 (36) 7 (10) 0 (0) 0.001 0.13
BOTH hips with synovitis or trochanteric bursitis 17 (21) 3 (4) 0 (0) 0.022 0.35
At least ONE shoulder and ONE hip with findings as above 26 (32) 6 (8) 0 (0) 0.003 0.18
BOTH shoulders and BOTH hips with findings as above 13 (16) 1 (1) 0 (0) 0.051 0.59
* McNemar’s test of agreement for Week 0 vs Week 26 among subjects with polymyalgia rheumatica (p < 0.001 for all comparisons of ultrasound findings).
Table 4. Response to corticosteroids (≥ 70% improvement) in patients with polymyalgia rheumatica (PMR).
Data are no. (%).
Feature Week 1, Week 4, Week 12, Week 26,
n = 77 n = 77 n = 79 n = 81
PMR VAS 31 (46) 52 (73) 56 (80) 52 (73)
Global pain VAS 27 (40) 48 (70) 56 (80) 50 (68)
Shoulder pain VAS 26 (38) 49 (68) 59 (82) 55 (72)
Hip pain VAS 33 (55) 49 (75) 51 (78) 54 (78)
Fatigue VAS 29 (43) 36 (52) 46 (66) 43 (59)
Duration of morning stiffness 48 (69) 68 (93) 69 (97) 69 (92)
Level of response*
Nonresponse 23 (47) 9 (16) 7 (12) 6 (10)
Partial response 22 (45) 18 (32) 21 (36) 19 (33)
Complete response 4 (8) 30 (53) 31 (52) 32 (56)
* Complete response defined as improved > 70% in PMR VAS, morning stiffness, and normal CRP and/or ESR;
partial response: only 2 of the 3; nonresponse: one or none of 3. VAS: visual analog scale; CRP: C-reactive pro-
tein; ESR: erythrocyte sedimentation rate.
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Factor analysis. Factor analysis was performed on the
changes between baseline and subsequent weeks to examine
the variable domains of the outcome measures (Table 6). A
total of 6 factors (or domains) were found to be sufficient to
represent all the outcome measures. These 6 domains were
PMR-related pain and physical function (PMR VAS, global
pain VAS, and shoulder VAS, MHAQ, and SF-36 PCS),
inflammatory markers (CRP and ESR), hip pain (hip VAS),
global pain, mental functioning (SF-36 MCS), and morning
stiffness. Internal consistency was assessed using Cronbach’s
alpha. There was almost perfect consistency between PMR
VAS, global pain VAS, and shoulder VAS in the first domain
(Cronbach’s alpha = 0.91; pairwise correlation coefficients
ranged from 0.73 to 0.86), indicating that these measures
were redundant. Internal consistency remained high
(Cronbach’s alpha = 0.79) when all 5 measures in the
PMR-related pain and physical functioning factor were con-
sidered together.
DISCUSSION
The goal of our study was to report on the disease course in
patients with PMR, and to assess the performance of various
PRO measures and their correlation with laboratory meas-
ures and response to CS therapy. We also sought to identify
a minimum set of outcome measures that can be used in
future clinical trials. Our findings indicate that the majority
of patients with PMR respond rapidly to CS treatment, and
show significant improvement in PRO measures, inflamma-
tory markers, and ultrasound findings. In addition, PRO
measures perform well in assessing disease activity in
patients with PMR. However, complete response is seen in
only about half the cases at Weeks 4 and 26, and up to 16%
801Matteson, et al: Patient-reported outcomes in PMR
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Table 5. Test-retest reliability of patient self-reported measures in 14 patients with polymyalgia rheumatica
(PMR) who had minimal change in PMR VAS (± 10 mm) between baseline and Week 1.
Scale Mean Maximum ICC SDD % MDC
PMR VAS 0–100 47.9 92 0.98 10.6 10.6
Global pain VAS 0–100 40.0 83 0.82 28.9 28.9
Shoulder pain VAS 0–100 46.2 96 0.77 34.7 34.7
Hip pain VAS 0–100 30.0 69 0.88 23.1 23.1
Fatigue VAS 0–100 37.7 73 0.32 57.4 57.4
MHAQ 0–3 0.89 1.9 0.72 0.78 25.9
SF-36 PCS 0–100 34.7 48.7 0.79 9.2 9.2
SF-36 MCS 0–100 49.0 62.9 0.30 16.7 16.7
Morning stiffness 0–1440 92.1 210.0 0.11 231 16.1
duration, min
ICC: Intraclass correlation coefficients; SDD: smallest detectable difference; %MDC: minimal detectable
change expressed as percentage of the maximum score; VAS: visual analog scale; PCS: physical component
score of the Medical Outcomes Study Short Form-36 (SF-36); MCS: mental component summary of the SF-36;
MHAQ: modified Health Assessment Questionnaire.
Table 6. Factor analysis: factor loadings for individual outcome measures.
Outcome Measure Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6
PMR VAS 0.89
Global pain VAS 0.68 0.60
Shoulder pain VAS 0.78
Hip pain VAS 0.90
Fatigue VAS*







* Only factor loadings > 0.5 are shown. VAS: visual analog scale; PCS: physical component score of the Medical
Outcomes Study Short Form-36 (SF-36); MCS: mental component summary of the SF-36; PMR: polymyalgia
rheumatica; MHAQ: modified Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; CRP: 
C-reactive protein.
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and 10% of cases fail to respond at Weeks 4 and 26, respec-
tively. We suggest that a minimum set of outcome measures
consisting of patient-reported global pain, hip pain, morning
stiffness, physical function (MHAQ), mental function, and
an inflammatory marker be used in practice and clinical tri-
als in PMR. Our study also indicates that all measures (clin-
ical, patient-reported, and laboratory measures) of disease
activity improve by 4 weeks. Therefore, future clinical stud-
ies, including those evaluating factors influencing CS
response and clinical trials of novel therapies, should have
their primary outcome evaluation early in the treatment
course, certainly by the 4-week timepoint after initiation of
treatment.
A future goal of our group is to consider all these
domains and measures for inclusion in the definition of dis-
ease activity to derive a composite disease activity score and
remission criteria incorporating these core domains. Our
findings complement a recently published literature search
and a Delphi-based expert consensus. That report10, among
other findings, highlights assessment of hip pain — a dis-
ease activity domain also found to be significant in our
prospective study. We need to be mindful of our test-retest
findings showing poor reliability for fatigue VAS and morn-
ing stiffness with large SDD for fatigue VAS. Combined
with the recently proposed classification criteria8, the next
step would be development of a validated score to be used
in protocols designed for randomized clinical trials of future
therapeutic agents.
Although previous studies have used several outcome
and clinical response measures, there is no consensus about
the optimal endpoints for evaluating efficacy of treatment in
PMR18. None of the previously proposed measures has been
validated, particularly use of patient-reported measures. A
PMR activity score has been proposed and assessed in 2
patient cohorts18. However, the validation cohorts suffered
from lack of clarity on eligibility, patient selection, and fol-
lowup assessments. Further, the assessments did not include
validated instruments for assessing function and quality of
life. They included the physician’s global assessment, a cri-
terion item that did not achieve 50% agreement in a consen-
sus and Delphi survey of relapse and remission in PMR10.
Previously used measures were somewhat arbitrary in
several respects, in particular with no consideration of the
validity of various measures at different stages of the dis-
ease, time/duration of the disease activity and remission
states, correlation with prognostic markers, and failure to
account for the continuity of the disease activity process.
The validity and sensitivity of measures can vary at differ-
ent stages of the disease course (e.g., pain resolves early but
laboratory markers of inflammation may remain high for
longer). Also, it is unknown whether a patient truly has
PMR even if he or she does not respond to CS treatment at
a specified dose. Our study shows that 16% and 10% did not
have a response to CS at 4 and 26 weeks, respectively.
Whether these patients have more severe PMR requiring
bigger CS doses and/or need disease-modifying drugs or
have an alternative diagnosis is the focus of our continuing
work.
Although not a primary outcome assessment, our finding
that patients with low mental SF-36 scores responded better
to CS therapy likely indicates that the disease/inflammatory
state is pathophysiologically relevant to mental function and
well-being. A previous PMR study found association of
MCS with inflammatory markers, suggesting neuropsycho-
logical effects of elevated circulating cytokines such as
interleukin 67. Future studies in PMR should include evalu-
ation of this important PRO. It is likely that the often-report-
ed fatigue is also related, and should be evaluated as an
important domain of outcome in future studies of PMR.
Disturbance of sleep by pain and stiffness (not measured in
our study) may be another contributory factor of low MCS
in patients with active PMR.
An exciting finding of our study is that characteristic
ultrasound abnormalities not only contribute to the classifi-
cation of patients with PMR7 but also are associated with a
good response to steroids at 4 weeks. We suggest that future
PMR clinical trials should evaluate ultrasound as an inde-
pendent measure of outcome alongside clinical and PRO
measures and laboratory markers, especially early in the
course of the disease. 
This international study is the first comprehensive
assessment of outcome measures in patients with PMR.
Standardized inclusion and exclusion criteria, standardized
CS treatment schedule, and standardized prospective data
collection at predefined intervals improve the validity of our
findings. This study brings together the expertise and com-
mitment of an international group of investigators who con-
tinue their efforts in this area. Validated and standardized
classification and outcome criteria in PMR will open the
way to well-designed clinical studies and new therapeutic
targets with the aim of improving patient care. Nevertheless,
the results should be interpreted in light of some potential
limitations. First, the external validity of the findings needs
to be evaluated in other prospective studies. Given the
uncertainties associated with the etiology of PMR, the out-
come criteria represent clinical outcomes and not biological
remission of the disease. The duration of followup (6
months) may be too short to identify longterm outcomes of
PMR, especially while off CS therapy. Patients in the study
had a range of disease severity; however, cases with GCA
were excluded, as they would be managed with different
treatment strategies. Future validation studies of the new
classification criteria and outcomes measures will offer the
opportunity to examine their utility across the disease spec-
trum of PMR.
The best measures of disease activity and treatment
response in PMR appear to be patient-reported global pain,
hip pain, morning stiffness, physical function (MHAQ),
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mental function, and an inflammatory marker. Ultrasound
may have utility in PMR classification as well as an out-
come measure. Our study also highlights the need for better
biomarkers of disease activity in PMR. 
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